Methods of using E2F2 for the treatment of hypertension

1. A method for ameliorating hypertension in a subject in need thereof, the method comprising;

(a) transforming an endothelial cell in vitro with an expression vector comprising a nucleic acid molecule encoding an E2F2 polypeptide fused to a protein transduction domain, wherein the protein transduction domain is selected from the group consisting of an HIV-TAT protein, a unidecapeptide protein transduction domain (YGRKKRRQRRR (SEQ ID NO: 2)), a polyarginine sequence, a VP22 domain, and a antennapedia protein transduction domain, wherein the E2F2 fusion polypeptide retains E2F2 activity;

(b) expressing the E2F2 polypeptide in the endothelial cell;

(c) isolating the E2F2 polypeptide; and

(d) administering the E2F2 polypeptide to the subject, thereby ameliorating the hypertension.

2. The method of claim 1 , wherein the endothelial cell in vitro is obtained from the subject.

3. A method for ameliorating hypertension in a subject in need thereof, the method comprising;

(a) transforming an endothelial cell in vitro with an expression vector comprising a nucleic acid molecule encoding an E2F2 polypeptide fused to a protein transduction domain selected from the group consisting of an HIV-TAT protein, a unidecapeptide protein transduction domain (YGRKKRRQRRR (SEQ ID NO: 2)), a polyarginine sequence, a VP22 domain, and a antennapedia protein transduction domain, wherein the E2F2 fusion polypeptide retains E2F2 activity;

(b) expressing the E2F2 fusion polypeptide in the endothelial cell; and

(c) administering the endothelial cell expressing the E2F2 fusion polypeptide to the subject, thereby ameliorating the hypertension.

4. The method of claim 3 , wherein the endothelial cell is a human cell.

5. The method of claim 3 , wherein the endothelial cell is a cardiac cell.

6. The method of claim 3 , wherein the endothelial cell in vitro is obtained from the subject.

7. A method of reducing hypertension in a subject in need thereof, the method comprising:

administering an effective amount of an E2F2 polypeptide having E2F2 activity to endothelial cells of the subject or

administering an effective amount of an E2F2 polypeptide fused to a protein transduction domain selected from the group consisting of an HIV-TAT protein, a unidecapeptide protein transduction domain (YGRKKRRQRRR (SEQ ID NO: 2)), a polyarginine sequence, a VP22 domain, and a antennapedia protein transduction domain to endothelial cells of the subject, wherein the E2F2 polypeptide fused to the protein transduction domain retains E2F2 activity.

8. The method of claim 7 , wherein the E2F2 activity of the E2F2 polypeptide or of the E2F2 polypeptide fused to the protein transduction domain activates an endothelial converting enzyme 1b (ECE-1b) promoter.

9. The method of claim 7 , wherein the hypertension is associated with a cardiovascular condition selected from the group consisting of cardiac hypertrophy, reduced systolic function, reduced diastolic function, maladaptive hypertrophy, heart failure with preserved systolic function, diastolic heart failure, hypertensive heart disease, aortic and mitral valve disease, pulmonary valve disease, hypertrophic cardiomyopathy, hypertrophic cardiomyopathy, post ischemic and post-infarction cardiac remodeling and cardiac failure.

10. The method of claim 7 , further comprising the step of measuring relaxation rate, cardiac contractility, cardiac ejection volume, or end-systolic volume, wherein a change in relaxation rate, cardiac contractility, cardiac ejection volume, or end-systolic volume is indicative of reducing hypertension.

11. The method of claim 7 , wherein the E2F2 polypeptide fused to the protein transduction domain is an E2F2 polypeptide fused to HIV-TAT protein that possesses E2F2 activity that activates an endothelial converting enzyme 1b (ECE-1b) promoter.